Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections (Q28371747)

2

0 references

Y Goto

3

0 references

Y Munechika

4

0 references

H Kodama

5

0 references

K Kanai

6

0 references

M Yoshida

7

0 references

T Miyazaki

8

0 references

H Yamaguchi

9

0 references

H Kodama

3

0 references

M Yoshida

4

0 references

T Miyazaki

5

0 references

H Yamaguchi

International Journal of Antimicrobial Agents

6

0 references

language of work or name

English

0 references

publication date

August 1999

0 references

April 1998

0 references

published in

0 references

Antimicrobial Agents and Chemotherapy

0 references

volume

12

0 references

42

0 references

page(s)

221-8

0 references

967-70

0 references

issue

3

0 references

4

0 references

cites work

Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Comparison of terbinafine and clotrimazole in treating tinea pedis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental tinea pedis in guinea pigs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Topical Clotrimazole in Tinea Pedis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Synthesis and antifungal activity of (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphtha lenemethanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Treatment of dermatomycoses with topical fenticonazole and econazole

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Sulconazole versus clotrimazole in the treatment of dermatophytosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Antifungal activity of the new agent latoconazole in two tinea models

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Therapeutic efficacy of latoconazole in formulations of clinical use on experimental dermatophytosis in guinea pigs

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

A study on effectiveness of treatment and prevention of relapse using topical administration of terbinafine in a guinea pig model for tinea pedis

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Treatment of Dermatomycoses with Topical Tioconazole and Miconazole

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105583

Tolerability and efficacy of bifonazole in dermatomycoses

27 November 2018

1 reference

12 December 2020

Experimental tinea pedis induced by non-abrasive inoculation of Trichophyton mentagrophytes arthrospores on the plantar part of a guinea pig foot

1 reference

12 December 2020

[Oxiconazole in dermatomycosis--a double-blind, randomized therapy compared with bifonazole]

1 reference

12 December 2020

Clinical evaluation of terconazole. European experience

1 reference

12 December 2020

Topical tioconazole in dermatomycosis

1 reference

12 December 2020

Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Overview of the treatment of disseminated fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Epidemiology of nosocomial fungal infections, with emphasis on Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Nosocomial pneumonia in patients having bone marrow transplant attributable mortality and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Epidemiology and control of fungal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Antifungal agents in the 1990s. Current status and future developments

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

The emerging fungal threat

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Amphotericin B nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Treatment of systemic fungal infections: recent progress and current problems

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Itraconazole, a new triazole that is orally active in aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Activity of SM-4470, a new imidazole derivative, against experimental fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Antimycotic activity of BAY N 7133 in animal experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Activity of ICI 195,739--a novel, orally active bistriazole--in rodent models of fungal and protozoal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

In vitro and in vivo antifungal activities of D0870, a new triazole agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Fluconazole-resistant candidosis in an HIV cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

High prevalence of antifungal resistance in Candida spp. from patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Pharmacokinetics of itraconazole following oral administration to normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Effect of cyclodextrin on the pharmacology of antifungal oral azoles

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900076-X

7 January 2021

10.1016/S0924-8579(99)00076-X

Identifiers

DOI

1 reference

4682264

4682264

1 reference

1 reference

0 references

1 reference